Pediatrix Medical Group Reports Q3 2026 Results with Increased Adjusted EPS
Pediatrix Medical Group (MD) reported third-quarter 2026 net revenue of $501.4 million, a 1.7% increase driven by acquisitions and modest same-unit growth. Despite facing inflationary pressures in clinical salaries and general expenses, the company achieved an adjusted EPS of $0.72, up from $0.67 in the prior-year period. Growth was supported by a favorable payer mix and increased demand in office-based patient services, though these gains were partially offset by declines in newborn nursery activity and NICU days. The company continues to prioritize shareholder returns, utilizing $83 million for share repurchases during the quarter as part of an ongoing 10-million-share buyback program. Management narrowed its full-year 2026 adjusted EBITDA outlook to a range of $290 million to $300 million. The company maintains a strong liquidity position with $311.9 million in cash and a low leverage ratio of approximately 1.0x.
Tickers: $MD
Topics: Adjusted EBITDA EPS Net Revenue Payer Mix Share Repurchases
Read the full article at Motley Fool
Part of the story Cloudflare Shares Surge Following Strong Q3 Results and Raised Full-Year Guidance (85 articles)